Published: July 30, 2013
WASHINGTON — Deep sequestration budget cuts have had “a devastating impact on federal court operations nationwide,” a top judicial official told a Senate committee last week.
Published: July 26, 2013
WASHINGTON – The rise in health care-related consumer debt, student loans,shoddy record keeping by creditors and abusive practices by debt collectors are leading federal regulators and lawmakers to crack down on third-party debt collectors and call for tighter rules applying to them.
WASHINGTON – This week’s Senate confirmation of Richard Cordray as director of the Consumer Financial Protection Bureau and the forward motion on the nominations to the National Labor Relations Board could ultimately lessen the blow of a potential U.S. Supreme Court decision invalidating the president’s recess appointments to those agencies.
WASHINGTON – Following two U.S. Supreme Court decisions that shut the door on state-law failure-to-warn and design-defect claims over generic drugs, the Food and Drug Administration is taking steps that could ultimately open a window for plaintiffs.
Now that the U.S. Supreme Court has ruled that the federal Defense of Marriage Act’s refusal to recognize state same-sex marriages was unconstitutional, employers are scrambling to figure out how far they have to go in changing their employee benefit and leave policies.
WASHINGTON — As lawsuits over the Patient Protection and Affordable Care Act’s contraception coverage mandate continue to work their way through courts across the country, federal regulators have finalized rules governing employer contraceptive coverage under the law.
WASHINGTON — The Food and Drug Administration has taken action against more than 9,600 websites, claiming they illegally sold potentially dangerous prescription drugs that put unwitting consumers at risk.
WASHINGTON — Enforcement of the federal health care law mandate requiring employers to provide health care coverage to workers or face a fine has been delayed for a year, the Obama administration announced Tuesday.
WASHINGTON – The U.S. Supreme Court’s decision barring state-law design-defect claims against generic drug makers that mirror failure-to-warn actions served a major setback to plaintiffs seeking damages for drug injuries.